A comparison of clinical and immunologic features in children and older patients hospitalized with severe cholera in Bangladesh

Pediatric Infectious Disease Journal

Volumn 27, Issue 11, 2008, Pages 986-992

  Chowdhury, Fahima ^a   Khan, Ashraful I ^a   Harris, Jason B ^b,c   Larocque, Regina C ^b,c   Chowdhury, Mohiul Islam ^a   Ryan, Edward T ^b,c,d   Faruque, A S G ^a   Calderwood, Stephen B ^b,c   Qadri, Firdausi ^a,e  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e ICDDRB Laboratory Sciences Division   (Bangladesh)

Author keywords

Children, older patients; Cholera; Immunological responses; Vibrio cholerae O1 O139

Indexed keywords

ANTIGEN; BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; PROTEIN TCPA; UNCLASSIFIED DRUG; CHOLERA TOXIN; FIMBRIA PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE; PERU 15; RETINOL; TCPA PROTEIN, VIBRIO CHOLERAE; ZINC;

ADOLESCENT; ARTICLE; BANGLADESH; CHILD; CHILD HOSPITALIZATION; CHOLERA; CLINICAL FEATURE; COHORT ANALYSIS; COMPARATIVE STUDY; DIARRHEA; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; RETINOL DEFICIENCY; VIBRIO CHOLERAE; ZINC DEFICIENCY; ADULT; AGING; BLOOD; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; PATHOPHYSIOLOGY;

ADOLESCENT; ADULT; AGING; BANGLADESH; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA TOXIN; CHOLERA VACCINES; COHORT STUDIES; FEMALE; FIMBRIAE PROTEINS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; VIBRIO CHOLERAE O1; VIBRIO CHOLERAE O139; VITAMIN A; ZINC;

EID: 58149174134     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181783adf     Document Type: Article

References (37)

1. Harris JB, Khan AI, LaRocque RC, et al. Blood group, immunity, and risk of infection with Vibrio choleraein an area of endemicity. Infect Immun. 2005;73:7422-7427.
2. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio choleraeO139 synonym Bengal. Lancet. 1993;342:387-390.
3. Sack RB, Siddique AK, Longini IM Jr, et al. A 4-year study of the epidemiology of Vibrio choleraein four rural areas of Bangladesh. J Infect Dis. 2003;187:96-101.
4. Faruque AS, Fuchs GJ, Albert MJ. Changing epidemiology of cholera due to Vibrio choleraeO1 and O139 Bengal in Dhaka, Bangladesh. Epidemiol Infect. 1996;116:275-278.
5. Albert MJ. Epidemiology & molecular biology of Vibrio cholerae O139 Bengal. Indian J Med Res. 1996;104:14-27.
6. Clemens JD, Sack DA, Harris JR, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet. 1990;335:270-273.
7. Suharyono Simanjuntak C, Witham N, et al. Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children. Lancet. 1992;340:689-694.
8. Lucas ME, Deen JL, von Seidlein L, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. N Eng J Med. 2005;352: 757-767.
9. Richie EE, Punjabi NH, Sidharta YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine. 2000;18:2399-2410.
10. Glass RI, Becker S, Huq MI, et al. Endemic cholera in rural Bangladesh, 1966-1980. Am J Epidemiol. 1982;116:959-970.
11. Agtini MD, Soeharno R, Lesmana M, et al. The burden of diarrhoea, shigellosis, and cholera in North Jakarta, Indonesia: findings from 24 months surveillance. BMC Infect Dis. 2005;5:89.
12. Mosley WH, Benenson AS, Barui R. A serological survey for cholera antibodies in rural East Pakistan. 2. A comparison of antibody titres in the immunized and control population of a cholera-vaccine field-trial area and the relation of antibody titre to cholera case rate. Bull WHO. 1968;38:335-346.
13. Taylor DN, Cardenas V, Perez J, Puga R, Svennerholm AM. Safety, immunogenicity, and lot stability of the whole cell/recombinant B subunit (WC/rCTB) cholera vaccine in Peruvian adults and children. Am J Trop Med Hyg. 1999;61:869-873.
14. Qadri F, Chowdhury MI, Faruque SM, et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine. 2007;25:231-238.
15. Qadri F, Chowdhury MI, Faruque SM, et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. InfectDis. 2005;192:573-579.
16. Diarrhoeal diseases control programme. Global activities, 1988-1989. Releve epidemiologique hebdomadaire/Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record/Health Section of the Secretariat of the League of Nations. 1990;65:289-292.
17. Albert MJ, Qadri F, Wahed MA, et al. Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine. J Infect Dis. 2003;187:909-913.
18. Qadri F, Azim T, Chowdhury A, et al. Production, characterization, and application of monoclonal antibodies to Vibrio choleraeO139 synonym Bengal. Clin Diagn Lab Immunol. 1994;1:51-54.
19. Qadri F, Mohi G, Hossain J, et al. Comparison of the vibriocidal antibody response in cholera due to Vibrio choleraeO139 Bengal with the response in cholera due to Vibrio choleraeO1. Clin Diagn Lab Immunol. 1995;2:685-688.
20. Asaduzzaman M, Ryan ET, John M, et al. The major subunit of the toxin-coregulated pilus TcpA induces mucosal and systemic immuno-globulin A immune responses in patients with cholera caused by Vibrio choleraeO1 and O139. Infect Immun. 2004;72:4448-4454.
21. Rollenhagen JE, Kalsy A, Cerda F, et al. Transcutaneous immunization with toxin-coregulated pilin A induces protective immunity against Vibrio choleraeO1 El tor challenge in mice. Infecti Immun. 2006;74: 5834-5839.
22. Qadri F, Ryan ET, Faruque AS, et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun. 2003;71:4808-4814.
23. Rabbani GH, Greenough WB III. Pathophysiology and Clinical Aspects ofCholera. New York, NY: Plenum; 1992.
24. Longini IM Jr, Yunus M, Zaman K, et al. Epidemic and endemic cholera trends over a 33-year period in Bangladesh. J Infect Dis. 2002;186:246-251.
25. Qadri F, Svennerholm AM, Faruque AS, et al. Enterotoxigenic Escherichia coliin developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev. 2005;18:465-483.
26. Krishnan S, Bhuyan UN, Talwar GP, et al. Effect of vitamin A and protein-calorie undernutrition on immune responses. Immunology. 1974; 27:383-392.
27. Fischer Walker CL, Black RE. Micronutrients and diarrheal disease. Clin Infect Dis. 2007;45(Suppl 1):S73-S77.
28. Qadri F, Ahmed T, Wahed MA, et al. Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine. Vaccine. 2004;22:416-421.
29. Roy SK, Tomkins AM, Ara G, et al. Impact of zinc deficiency on Vibrio choleraeenterotoxin-stimulated water and electrolyte transport in animal model. JHealth Popul Nutr. 2006;24:42-47.
30. Khan AM, Larson CP, Faruque AS, et al. Introduction of routine zinc therapy for children with diarrhoea: evaluation of safety. JHealth Popul Nutr. 2007;25:127-133.
31. Baqui AH, Black RE, Fischer Walker CL, et al. Zinc supplementation and serum zinc during diarrhea. Indian J Pediatr. 2006;73:493-497.
32. Karlsen TH, Sommerfelt H, Klomstad S, et al. Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation. Infect Immun. 2003; 71:3909-3913.
33. Ali M, Emch M, von Seidlein L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet. 2005; 366:44-49.
34. Sharma NC, Mandal PK, Dhillon R, Jain M. Changing profile of Vibrio choleraeO1, O139 in Delhi and its periphery (2003-2005). Indian J Med Res. 2007;125:633-640.
35. Sur D, Deen JL, Manna B, et al. The burden of cholera in the slums of Kolkata, India: data from a prospective, community based study. Arch Dis Child. 2005;90:1175-1181.
36. Rijkers GT, Dollekamp I, Zegers BJ. 8-Mercaptoguanosine overcomes unresponsiveness of human neonatal B cells to polysaccharide antigens. JImmunol. 1988;141:2313-2316.
37. Glass RI, Svennerholm AM, Stoll BJ, et al. Effects of undernutrition on infection with Vibrio choleraeO1 and on response to oral cholera vaccine. Pediatr Infect Dis J. 1989;8:105-109.